Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab New Maintenance Dosing Regimen in Relapsing Multiple Sclerosis
NCT06869785Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Mar 2025
- Primary completion
- Jan 2026
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of ofatumumab in multiple sclerosis (MS) (2 arms), sponsored by Novartis. Primary endpoint: Ofatumumab plasma pharmacokinetics - area under the curve at 12 weeks. Started Mar 2025; status: active, not recruiting.
02
Drugs
ofatumumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT06869785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06869785.